North Carolina · Q5101

Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram in North Carolina

North Carolina Medicare Avg
$0.15
4% below national avg
National Medicare Avg
$0.16
All states combined
Billed Charge (NC)
$2.61
What providers submit
Est. Commercial (NC)
$0.44
National avg: $0.45
Est. Cash / Self-Pay (NC)
$0.87
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

93.6K
Services in NC
31
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in North Carolina

Provider Medicare Services
Schaefer-Cutillo, Julia M.D. $0.16 35.7K
Gajurel, Kiran MD $0.15 11.0K

North Carolina Pricing in Context

In North Carolina, CPT code Q5101 (Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram) carries an average Medicare payment of $0.15 — 4% below the national benchmark of $0.16. 31 providers across the state submitted claims for this procedure in 2023, performing 93.6K total services. Individual payments in NC ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in North Carolina is $2.61, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because North Carolina sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Codes procedures, the estimated commercial insurance price in North Carolina lands near $0.44, with self-pay cash prices typically around $0.87. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram cost in North Carolina?

The average Medicare payment for Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram in North Carolina is $0.15, which is 4% below the national average of $0.16. Providers in NC typically bill $2.61 for this procedure.

What does Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram cost with insurance in North Carolina?

With commercial insurance in North Carolina, Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram costs an estimated $0.44. Without insurance, the estimated cash price is $0.87. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram in North Carolina?

31 providers in North Carolina billed Medicare for Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram in 2023, performing 93.6K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram cheaper in North Carolina than the national average?

Yes — Injection, Filgrastim-Sndz, Biosimilar, (zarxio), 1 Microgram costs 4% below the national average in North Carolina. The state average Medicare payment is $0.15 compared to $0.16 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial